Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05HTS
|
|||
| Former ID |
DIB012524
|
|||
| Drug Name |
PLX8394
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [2] | ||
| Company |
Daiichi sankyo parsippany
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H21F3N6O3S
|
|||
| Canonical SMILES |
C1CC1C2=NC=C(C=N2)C3=CC4=C(NC=C4C(=O)C5=C(C=CC(=C5F)NS(=O)(=O)N6CCC(C6)F)F)N=C3
|
|||
| InChI |
1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)/t16-/m1/s1
|
|||
| InChIKey |
YYACLQUDUDXAPA-MRXNPFEDSA-N
|
|||
| CAS Number |
CAS 1393466-87-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02428712) A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors. U.S. National Institutes of Health. | |||
| REF 3 | Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.